MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Johnson and Johnson

Gesloten

SectorGezondheidszorg

155.4 1.44

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

153.18

Max

155.77

Belangrijke statistieken

By Trading Economics

Inkomsten

3.4B

Verkoop

20M

23B

K/W

Sectorgemiddelde

28.643

63.778

EPS

2.04

Dividendrendement

2.99

Winstmarge

15.235

Werknemers

138,100

EBITDA

652M

5.9B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+9.9% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.99%

2.39%

Volgende Winsten

15 apr 2025

Volgende Ex Dividend datum

19 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

32B

400B

Vorige openingsprijs

153.96

Vorige sluitingsprijs

155.4

Nieuwssentiment

By Acuity

62%

38%

339 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

Johnson and Johnson Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 mrt 2025, 15:16 UTC

Belangrijke Marktbewegers

Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option

10 mrt 2025, 13:59 UTC

Belangrijke Marktbewegers

Protagonist Therapeutics Shares Rise After Positive Trial Data for Icotronkinra

2 apr 2025, 12:49 UTC

Acquisities, Fusies, Overnames

Johnson & Johnson Expects 2026 Earnings Dilution to Be Reduced to About 21c/Shr

2 apr 2025, 12:49 UTC

Acquisities, Fusies, Overnames

Johnson & Johnson Expects Deal to Dilute Adj EPS by About 25c in 2025 >JNJ

2 apr 2025, 12:48 UTC

Acquisities, Fusies, Overnames

J&J: Deal Expected to Accelerate 2025 Sales Growth by About 0.8% With About $700M in Incremental Sales >JNJ

2 apr 2025, 12:45 UTC

Acquisities, Fusies, Overnames

J&J: Addition of CAPLYTA Strengthens Lineup of Therapies With $5 Billion+ Potential in Peak Yr Sales >JNJ

2 apr 2025, 12:44 UTC

Acquisities, Fusies, Overnames

Johnson & Johnson: sNDA Submitted to FDA for CAPLYTA as Adjunctive Treatment for Major Depressive Disorder >JNJ

2 apr 2025, 12:44 UTC

Acquisities, Fusies, Overnames

Johnson & Johnson Closes Landmark Intra-Cellular Therapies Acquisition to Solidify Neuroscience Leadership

1 apr 2025, 20:07 UTC

Acquisities, Fusies, Overnames

Johnson & Johnson Intends to Complete Its Acquisition of Intra-Cellular Therapies on or Around April 2 >JNJ

1 apr 2025, 16:09 UTC

Winsten

These Stocks Are Moving the Most Today: Tesla, Johnson & Johnson, Southwest, Delta, MicroStrategy, PVH, Newsmax, and More -- Barrons.com

1 apr 2025, 13:51 UTC

Winsten

These Stocks Are Moving the Most Today: Tesla, Johnson & Johnson, PVH, Southwest, Newsmax, and More -- Barrons.com

1 apr 2025, 12:15 UTC

Top Nieuws

Johnson & Johnson Stock Falls After Latest Talc Resolution Rejected -- Barrons.com

1 apr 2025, 11:37 UTC

Marktinformatie

Johnson & Johnson To Reverse $7 Billion of Talc Reserve -- Market Talk

1 apr 2025, 10:36 UTC

Winsten

These Stocks Are Moving the Most Today: Tesla, XPeng, PVH, Progress Software, J&J, Newsmax, Southwest, and More -- Barrons.com

1 apr 2025, 01:04 UTC

Top Nieuws

Johnson & Johnson's Third Bankruptcy Case for Talc Lawsuits Thrown Out -- WSJ

21 mrt 2025, 23:02 UTC

Acquisities, Fusies, Overnames

Ranking the S&P 500s Most Defensive Stocks -- Barrons.com

21 mrt 2025, 13:35 UTC

Winsten
Populaire aandelen

Stocks to Watch Friday: J&J, Nike, FedEx, Micron -- WSJ

14 mrt 2025, 09:30 UTC

Top Nieuws

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

7 mrt 2025, 01:00 UTC

Top Nieuws

Finance Executives Seek Stability Amid Erratic Tariff Shifts -- WSJ

18 feb 2025, 22:22 UTC

Top Nieuws

Johnson & Johnson Goes to Trial on Third Talc Bankruptcy Plan -- Update

14 feb 2025, 13:00 UTC

Top Nieuws

J&J's High Hopes for Heart-Rhythm Device Grounded by Safety Concerns -- WSJ

24 jan 2025, 07:00 UTC

Top Nieuws

Disasters Spawn New Businesses. The California Wildfires Will Do the Same. -- Barrons.com

22 jan 2025, 21:39 UTC

Winsten

These Stocks Moved the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More -- Barrons.com

22 jan 2025, 19:41 UTC

Winsten

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More -- Barrons.com

22 jan 2025, 17:38 UTC

Marktinformatie
Winsten

J&J's Forex Headwind in Outlook Surprised Investors -- Market Talk

22 jan 2025, 16:48 UTC

Winsten

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More -- Barrons.com

22 jan 2025, 14:51 UTC

Winsten

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Ford, and More -- Barrons.com

22 jan 2025, 14:09 UTC

Top Nieuws
Winsten

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

22 jan 2025, 13:04 UTC

Winsten

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, J&J, Procter & Gamble, United, Travelers, and More -- Barrons.com

22 jan 2025, 12:47 UTC

Winsten

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, J&J, Procter & Gamble, United, Agilysys, and More -- Barrons.com

Peer Vergelijking

Prijswijziging

Johnson and Johnson Prognose

Koersdoel

By TipRanks

9.9% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 168.42 USD  9.9%

Hoogste 185 USD

Laagste 152 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Johnson and Johnson - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

14 ratings

6

Buy

8

Hold

0

Sell

Technische score

By Trading Central

N/A / 164.25Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

339 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.